Indivior PLC Ordinary Share INDV
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if INDV is a good fit for your portfolio.
News
-
Indivior Announces Q1 2024 Financial Results
-
Indivior Announces Publication Demonstrating that OPVEE® (nalmefene) Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal Naloxone
-
Court Provides Final Approval of Settlement with Direct Purchaser Class in the Multidistrict Antitrust Litigation; Final Court Approval Concludes the Antitrust Multidistrict Litigation
-
Indivior Announces Q4 / FY 2023 Financial Results
-
Indivior Says UK High Court Strikes Claims Against It and Reckitt Benckiser
-
Indivior's Overdose-Reversal Nasal Spray Gets FDA Approval
Trading Information
- Previous Close Price
- GBX 1,400.00
- Day Range
- GBX 1,363.00–1,426.00
- 52-Week Range
- GBX 1,125.00–1,938.00
- Bid/Ask
- GBX 0.00 / GBX 0.00
- Market Cap
- GBX 190.74 Bil
- Volume/Avg
- 660,758 / 515,197
Key Statistics
- Price/Earnings (Normalized)
- 7.71
- Price/Sales
- 2.21
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 2.31%
Company Profile
Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs for treatment of substance use disorders and other serious mental illnesses. Its products include, Sublocade, Perseris, Suboxone, Opvee among others. The vast majority of Indivior's revenue is generated in the United States, followed by United Kingdom and the rest of the world.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Core
- Total Number of Employees
- 1,164
- Website
- https://www.indivior.com
Comparables
Valuation
|
Metric
|
INDV
|
FUM
|
ERGO
|
|---|---|---|---|
Price/Earnings (Normalized) | 7.71 | — | 31.20 |
Price/Book Value | 240.19 | 19.48 | 8.19 |
Price/Sales | 2.21 | 33.67 | 4.55 |
Price/Cash Flow | — | — | 35.25 |
Price/Earnings
INDV
FUM
ERGO
Financial Strength
|
Metric
|
INDV
|
FUM
|
ERGO
|
|---|---|---|---|
Quick Ratio | 0.68 | 1.46 | 1.72 |
Current Ratio | 0.92 | 1.47 | 1.79 |
Interest Coverage | 0.11 | — | 30.39 |
Quick Ratio
INDV
FUM
ERGO
Profitability
|
Metric
|
INDV
|
FUM
|
ERGO
|
|---|---|---|---|
Return on Assets (Normalized) | 12.41% | −40.96% | 17.36% |
Return on Equity (Normalized) | 620.00% | −64.70% | 28.99% |
Return on Invested Capital (Normalized) | 68.45% | −65.22% | 26.30% |
Return on Assets
INDV
FUM
ERGO
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
MKKGY
| Merck KGaA ADR | Dckwpyxwv | Rlsppv | $69.8 Bil | |
ZTS
| Zoetis Inc Class A | Pmqcwhyffl | Ylt | $68.9 Bil | |
HLN
| Haleon PLC ADR | Sfqknmrdf | Kmzvn | $37.7 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Qpygzfstz | Jtfs | $14.8 Bil | |
VTRS
| Viatris Inc | Lnhlnhw | Twwh | $13.6 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Hmvqbfpc | Chmm | $11.9 Bil | |
CTLT
| Catalent Inc | Szfkmyxk | Pvmvzfj | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Lhhcbslbx | Kccv | $4.2 Bil | |
CURLF
| Curaleaf Holdings Inc | Fqbkszfs | Mtg | $3.6 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Mkbykpc | Hdkpcp | $3.5 Bil |